Related Experiment Video
Updated: Jun 15, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Procalcitonin as a prognostic marker in patients with acute myocardial infarction
Dominic Kelly1, Sohail Q Khan, Onkar Dhillon
1Department of Cardiovascular Sciences, University of Leicester, Leicester Royal Infirmary, Leicester, UK. kelly.dominic@talk21.com
Insights
Elevated procalcitonin levels after acute myocardial infarction (AMI) are linked to major adverse cardiac events (MACE). This inflammatory marker also correlates with impaired left ventricular (LV) function and adverse cardiac remodelling post-AMI.
Area of Science:
- Cardiology
- Biomarkers
- Inflammation
Background:
- Procalcitonin (PCT) is a key inflammatory mediator.
- PCT elevation is linked to poor prognosis in various clinical settings.
Purpose of the Study:
- To examine the relationship between PCT levels and major adverse cardiac events (MACE).
- To assess the association of PCT with left ventricular (LV) function and remodelling after acute myocardial infarction (AMI).
Main Methods:
- Plasma PCT levels were quantified in 977 patients diagnosed with AMI.
- Patients were monitored for MACE over a median follow-up of 671 days.
- Echocardiography was performed in a subset of patients to evaluate LV function and volumes at discharge and follow-up.
Main Results:
- Procalcitonin levels showed a significant association with MACE in both univariate and multivariable analyses.
- Kaplan-Meier survival analysis indicated poorer outcomes for patients with PCT levels above the median.
- PCT levels correlated with indicators of LV dysfunction and cardiac remodelling.
Conclusions:
- Procalcitonin serves as a prognostic biomarker in the context of AMI.
- Elevated PCT is associated with an increased risk of MACE, LV dysfunction, and adverse LV remodelling following AMI.
Background:
Procalcitonin is involved in the inflammatory response and is associated with adverse prognosis in certain conditions.
Aims:
To investigate the association between procalcitonin and major adverse cardiac events (MACE), left ventricular (LV) function and remodelling following acute myocardial infarction (AMI).
Methods:
Plasma procalcitonin was measured in 977 patients with AMI. Subjects were followed for MACE (median 671 days). A subgroup underwent echocardiography at discharge and follow-up LV function and volume assessment.
Results:
Procalcitonin was associated with MACE on uni- and multivariable analysis. Kaplan-Meier assessment revealed an adverse outcome in subjects with procalcitonin above the median. Procalcitonin was related to markers of LV dysfunction and remodelling.
Conclusion:
Procalcitonin is associated with MACE, LV dysfunction and remodelling post-AMI.
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Myocarditis II: Clinical Features and Diagnostic Tests
Pericarditis II: Clinical Features and Diagnostic Tests
